AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
aripiprazole lauroxil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| psychotropics, phenylpiperazine derivatives | 5052 | 1259305-29-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
prodrug of aripiprazole, following intramuscular injection is converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole which is then hydrolyzed to aripiprazole
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 5, 2015 | FDA | ALKERMES |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Needle issue | 1025.83 | 45.64 | 201 | 2828 | 13733 | 90611685 |
| Off label use | 489.45 | 45.64 | 349 | 2680 | 1101903 | 89523515 |
| Syringe issue | 294.88 | 45.64 | 58 | 2971 | 3944 | 90621474 |
| Injection site pain | 292.02 | 45.64 | 133 | 2896 | 173566 | 90451852 |
| Wrong technique in device usage process | 290.29 | 45.64 | 61 | 2968 | 5774 | 90619644 |
| Product administered at inappropriate site | 221.46 | 45.64 | 46 | 2983 | 4105 | 90621313 |
| Injection site mass | 214.06 | 45.64 | 62 | 2967 | 22028 | 90603390 |
| Incorrect dose administered | 166.19 | 45.64 | 71 | 2958 | 78859 | 90546559 |
| Hallucination, auditory | 155.40 | 45.64 | 45 | 2984 | 15930 | 90609488 |
| Product physical consistency issue | 128.49 | 45.64 | 23 | 3006 | 931 | 90624487 |
| Injection site induration | 104.04 | 45.64 | 30 | 2999 | 10438 | 90614980 |
| Therapeutic response shortened | 103.64 | 45.64 | 36 | 2993 | 22843 | 90602575 |
| Wrong technique in product usage process | 95.69 | 45.64 | 47 | 2982 | 71524 | 90553894 |
| Product administration error | 83.93 | 45.64 | 32 | 2997 | 26391 | 90599027 |
| Product leakage | 65.82 | 45.64 | 14 | 3015 | 1394 | 90624024 |
| Paranoia | 65.01 | 45.64 | 22 | 3007 | 12886 | 90612532 |
| Inappropriate schedule of product administration | 56.86 | 45.64 | 44 | 2985 | 149889 | 90475529 |
| Weight increased | 54.08 | 45.64 | 68 | 2961 | 417859 | 90207559 |
| Occupational exposure to product | 52.57 | 45.64 | 13 | 3016 | 2518 | 90622900 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Needle issue | 801.07 | 57.28 | 174 | 3055 | 8553 | 42609553 |
| Product administered at inappropriate site | 501.17 | 57.28 | 99 | 3130 | 2999 | 42615107 |
| Injection site pain | 310.81 | 57.28 | 128 | 3101 | 57670 | 42560436 |
| Off label use | 285.36 | 57.28 | 289 | 2940 | 638046 | 41980060 |
| Wrong technique in device usage process | 224.50 | 57.28 | 50 | 3179 | 2707 | 42615399 |
| Hallucination, auditory | 196.31 | 57.28 | 64 | 3165 | 14800 | 42603306 |
| Therapeutic response shortened | 169.43 | 57.28 | 56 | 3173 | 13498 | 42604608 |
| Syringe issue | 163.96 | 57.28 | 49 | 3180 | 8507 | 42609599 |
| Incorrect dose administered | 155.32 | 57.28 | 77 | 3152 | 52897 | 42565209 |
| Product physical consistency issue | 103.52 | 57.28 | 22 | 3207 | 951 | 42617155 |
| Injection site mass | 78.15 | 57.28 | 28 | 3201 | 8547 | 42609559 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Needle issue | 1469.06 | 47.11 | 300 | 4975 | 17540 | 110566484 |
| Off label use | 586.27 | 47.11 | 512 | 4763 | 1499673 | 109084351 |
| Injection site pain | 525.46 | 47.11 | 225 | 5050 | 177697 | 110406327 |
| Product administered at inappropriate site | 515.49 | 47.11 | 103 | 5172 | 5290 | 110578734 |
| Wrong technique in device usage process | 404.85 | 47.11 | 88 | 5187 | 6813 | 110577211 |
| Syringe issue | 360.82 | 47.11 | 85 | 5190 | 9440 | 110574584 |
| Hallucination, auditory | 300.55 | 47.11 | 91 | 5184 | 26306 | 110557718 |
| Injection site mass | 255.26 | 47.11 | 79 | 5196 | 24534 | 110559490 |
| Incorrect dose administered | 252.99 | 47.11 | 115 | 5160 | 103526 | 110480498 |
| Therapeutic response shortened | 209.07 | 47.11 | 71 | 5204 | 29512 | 110554512 |
| Product physical consistency issue | 202.21 | 47.11 | 38 | 5237 | 1402 | 110582622 |
| Injection site induration | 119.87 | 47.11 | 37 | 5238 | 11346 | 110572678 |
| Product dose omission issue | 105.34 | 47.11 | 101 | 5174 | 321681 | 110262343 |
| Weight increased | 103.43 | 47.11 | 113 | 5162 | 419531 | 110164493 |
| Wrong technique in product usage process | 101.83 | 47.11 | 59 | 5216 | 87289 | 110496735 |
| Product leakage | 91.26 | 47.11 | 20 | 5255 | 1598 | 110582426 |
| Inappropriate schedule of product administration | 90.48 | 47.11 | 76 | 5199 | 203561 | 110380463 |
| Product administration error | 83.40 | 47.11 | 39 | 5236 | 37178 | 110546846 |
| Paranoia | 81.40 | 47.11 | 33 | 5242 | 22341 | 110561683 |
| Anxiety | 71.46 | 47.11 | 85 | 5190 | 344993 | 110239031 |
| Restlessness | 68.19 | 47.11 | 39 | 5236 | 56220 | 110527804 |
| Treatment noncompliance | 66.21 | 47.11 | 42 | 5233 | 72948 | 110511076 |
| Soliloquy | 59.62 | 47.11 | 13 | 5262 | 1014 | 110583010 |
| Anger | 58.89 | 47.11 | 25 | 5250 | 18982 | 110565042 |
| Mania | 53.51 | 47.11 | 24 | 5251 | 20772 | 110563252 |
| Abnormal behaviour | 52.55 | 47.11 | 29 | 5246 | 39010 | 110545014 |
| Feeling abnormal | 52.07 | 47.11 | 53 | 5222 | 180658 | 110403366 |
| Product administered by wrong person | 50.22 | 47.11 | 8 | 5267 | 108 | 110583916 |
| Restless legs syndrome | 49.63 | 47.11 | 24 | 5251 | 24602 | 110559422 |
| Underdose | 48.90 | 47.11 | 33 | 5242 | 63521 | 110520503 |
| Thinking abnormal | 47.18 | 47.11 | 20 | 5255 | 15120 | 110568904 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
| MeSH PA | D014150 | Antipsychotic Agents |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35941 | serotonergic agonist |
| CHEBI has role | CHEBI:37955 | H<small><sub>1</sub></small>-receptor antagonist |
| CHEBI has role | CHEBI:50266 | prodrug |
| CHEBI has role | CHEBI:65191 | second generation antipsychotic |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.84 | Basic |
| pKa2 | 0.67 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10112903 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 8796276 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10112903 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 8796276 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10112903 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 8796276 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10112903 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 8796276 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 675MG/2.4ML (281.25MG/ML) | ARISTADA INITIO KIT | ALKERMES INC | N209830 | June 29, 2018 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10112903 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 675MG/2.4ML (281.25MG/ML) | ARISTADA INITIO KIT | ALKERMES INC | N209830 | June 29, 2018 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 8796276 | June 24, 2030 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10226458 | March 19, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10226458 | March 19, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10226458 | March 19, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10226458 | March 19, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9034867 | Nov. 7, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9034867 | Nov. 7, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9034867 | Nov. 7, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9034867 | Nov. 7, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 12629366 | Dec. 6, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 12629366 | Dec. 6, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 12629366 | Dec. 6, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 12629366 | Dec. 6, 2032 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11097006 | Sept. 19, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 12311027 | Sept. 19, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11097006 | Sept. 19, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 12311027 | Sept. 19, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11097006 | Sept. 19, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 12311027 | Sept. 19, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11097006 | Sept. 19, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 12311027 | Sept. 19, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9193685 | Oct. 24, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9193685 | Oct. 24, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9193685 | Oct. 24, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9193685 | Oct. 24, 2033 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10238651 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10813928 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INJECTION |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11406632 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9452131 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10238651 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10813928 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INJECTION |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11406632 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9452131 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10238651 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10813928 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INJECTION |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11406632 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9452131 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10238651 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10813928 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11406632 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 9452131 | March 19, 2035 | TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION |
| 675MG/2.4ML (281.25MG/ML) | ARISTADA INITIO KIT | ALKERMES INC | N209830 | June 29, 2018 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 10849894 | Aug. 17, 2035 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11273158 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
| 1064MG/3.9ML (272.82MG/ML) | ARISTADA | ALKERMES INC | N207533 | June 5, 2017 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 12251381 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11273158 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
| 441MG/1.6ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 12251381 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11273158 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
| 662MG/2.4ML (275.83MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 12251381 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11273158 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
| 882MG/3.2ML (275.63MG/ML) | ARISTADA | ALKERMES INC | N207533 | Oct. 5, 2015 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 12251381 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
| 675MG/2.4ML (281.25MG/ML) | ARISTADA INITIO KIT | ALKERMES INC | N209830 | June 29, 2018 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 11273158 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
| 675MG/2.4ML (281.25MG/ML) | ARISTADA INITIO KIT | ALKERMES INC | N209830 | June 29, 2018 | RX | SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 12251381 | April 6, 2039 | TREATMENT OF SCHIZOPHRENIA |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | PARTIAL AGONIST | Ki | 9.47 | DRUG LABEL | DRUG LABEL | |||
| 5-hydroxytryptamine receptor 1A | GPCR | PARTIAL AGONIST | Ki | 8.77 | DRUG LABEL | DRUG LABEL | |||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 8.47 | DRUG LABEL | DRUG LABEL | |||
| 5-hydroxytryptamine receptor 1B | GPCR | AGONIST | Ki | 6.10 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 7 | GPCR | Ki | 7.41 | DRUG LABEL | |||||
| D(3) dopamine receptor | GPCR | Ki | 9.10 | DRUG LABEL | |||||
| Histamine H1 receptor | GPCR | Ki | 7.22 | DRUG LABEL | |||||
| D(4) dopamine receptor | GPCR | Ki | 7.36 | DRUG LABEL | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 7.82 | DRUG LABEL | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | AGONIST | Ki | 7.20 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2A | GPCR | AGONIST | Ki | 7.70 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 7 | GPCR | AGONIST | Ki | 7.80 | IUPHAR | ||||
| D(4) dopamine receptor | GPCR | ANTAGONIST | Ki | 7.30 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 6 | GPCR | AGONIST | Ki | 6.80 | IUPHAR | ||||
| D(2) dopamine receptor | GPCR | AGONIST | Ki | 9.70 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| B786J7A343 | UNII |
| D10364 | KEGG_DRUG |
| 4034891 | VANDF |
| C4056439 | UMLSCUI |
| CHEMBL2219425 | ChEMBL_ID |
| 49831411 | PUBCHEM_CID |
| DB14185 | DRUGBANK_ID |
| C000603935 | MESH_SUPPLEMENTAL_RECORD_UI |
| 1673265 | RXNORM |
| 236432 | MMSL |
| 31226 | MMSL |
| 016489 | NDDF |
| 017628 | NDDF |
| 715182007 | SNOMEDCT_US |
| CHEBI:90930 | CHEBI |
| B786J7A343 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ARISTADA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-401 | INJECTION, SUSPENSION, EXTENDED RELEASE | 441 mg | INTRAMUSCULAR | NDA | 29 sections |
| ARISTADA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-402 | INJECTION, SUSPENSION, EXTENDED RELEASE | 662 mg | INTRAMUSCULAR | NDA | 29 sections |
| ARISTADA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-403 | INJECTION, SUSPENSION, EXTENDED RELEASE | 882 mg | INTRAMUSCULAR | NDA | 29 sections |
| ARISTADA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-404 | INJECTION, SUSPENSION, EXTENDED RELEASE | 1064 mg | INTRAMUSCULAR | NDA | 29 sections |
| ARISTADA INITIO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65757-500 | INJECTION, SUSPENSION, EXTENDED RELEASE | 675 mg | INTRAMUSCULAR | NDA | 29 sections |